CEGAT GMBH

Company Overview

CeGaT GmbH, founded in 2009, markets a range of NGS-based clinical tests for cancer and other diseases. The company uses the HiSeq 2500, MiSeq, and Ion Torrent PGM sequencing platforms. CeGaT markets more than 160 NGS-based diagnostic tests for hereditary disorders and hereditary cancers as well as a somatic tumor panel (sequences of more than 550 genes) and germline tumor syndromes. These tests use HiSeq 2500 instruments to sequence the whole exomes of cancer-relevant genes.

Sequencing tests include genome sequencing, targeted sequencing, restriction site-associated DNA sequencing, RNA sequencing and metagenome sequencing. In the field of sequencing-based liquid biopsy, CeGaT markets the Harmony test, which detects chromosomal disorders in unborn children. CeGaT team consists of highly qualified professionals with expertise in different skills. The company uses advanced technologies with features designed to sequence large quantities of samples in short time periods. CeGaT is accredited with CAP, CLIA, and DIN EN ISO 15189:2014 certifications.

In February 2017, CeGaT received funding (approximately $530,000) from the German Federal Ministry of Education and Research for liquid biopsy research. This will enable CeGaT to develop assays for monitoring cancer for patients who cannot safely have a tissue biopsy. As a result of this funding, CeGaT now offers liquid biopsy services to customers. This service involves extracting cfDNA from plasma and analysis by sequencing or digital PCR.

In 2018, CeGaT and B. Braun China formed a partnership to market clinical genetic testing services in China. This expanded CeGaT’s geographic footprint for its liquid biopsy testing business in Asia.

Company's Business Segments

• Genetic Analysis : Genetic Analysis provide Researchers, Pharmaceutical Companies with Genetic Analysis for Clinical Trials, Medical Innovation. It also used for for a wide range of Medical, Research, Pharmaceutical Applications.